United States Patent 7,514,444: Scope, Claims, Ibrutinib Coverage, and Patent Landscape
U.S. Patent No. 7,514,444 is a foundational compound patent covering ibrutinib and related Bruton's tyrosine kinase (BTK) inhibitors. The patent claims a genus of substituted pyrazolo[3,4-d]pyrimidines, specific acrylamide and related electrophilic derivatives, pharmaceutical compositions, and selected stereoisomers. Its most commercially important disclosed compound is ibrutinib, marketed as Imbruvica by Pharmacyclics, Janssen and AbbVie.
The patent's principal compound protection is scheduled to expire on March 6, 2026, subject to any applicable patent-term adjustment or pediatric extension. Later patents, regulatory exclusivities, litigation settlements and formulation claims have extended practical barriers to unrestricted generic competition beyond the expiration of the core compound patent.
What drug does U.S. Patent 7,514,444 protect?
The patent protects compounds built around a 4-amino-3-aryl-1H-pyrazolo[3,4-d]pyrimidine pharmacophore. Claim 5 expressly recites ibrutinib and closely related analogues.
Ibrutinib is:
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
Its key structural elements are:
| Structural element |
Ibrutinib feature |
| Core |
4-amino-1H-pyrazolo[3,4-d]pyrimidine |
| Aryl substituent |
4-phenoxyphenyl |
| Linker ring |
Chiral 3-substituted piperidine |
| Electrophile |
N-acryloyl group |
| Reactive function |
Acrylamide Michael acceptor |
| Primary target |
Bruton's tyrosine kinase |
| Product |
Imbruvica |
| Active ingredient |
Ibrutinib |
The acrylamide forms a covalent bond with cysteine 481 in BTK. This covalent mechanism distinguishes ibrutinib from reversible BTK inhibitors such as pirtobrutinib.
What are the main claim categories in Patent 7,514,444?
The claims operate at four levels: a broad chemical genus, narrower structural subclasses, specifically named compounds, and pharmaceutical compositions.
Claim 1: Broad compound genus
Claim 1 covers compounds of Formula D with the following principal limitations:
- La is oxygen or sulfur.
- Ar is unsubstituted phenyl.
- Y is a 4-, 5-, 6- or 7-membered cycloalkyl ring, or azetidinyl, pyrrolidinyl, piperidinyl or azepanyl.
- Z is carbonyl, oxycarbonyl, aminocarbonyl, sulfonyl or aminosulfonyl.
- R8 is hydrogen.
- R7 and R6 may be hydrogen, selected alkyl, alkoxyalkyl, alkylaminoalkyl or alkylphenyl groups.
- R7 and R8 may jointly form a bond.
- Pharmaceutically acceptable salts are included.
This is a Markush claim. It does not protect only ibrutinib. It covers a family of analogues sharing the specified core and substituent architecture.
The claim is commercially important because it reaches compounds that vary the ring system and the electrophilic substituent while retaining the 4-phenoxyphenyl pyrazolopyrimidine framework.
Claims 2 through 4: Narrower oxygen and linker limitations
Claim 2 limits La to oxygen. This excludes sulfur-containing analogues.
Claim 3 limits Z to:
- C(=O);
- NHC(=O); or
- S(=O)2.
Claim 4 limits the R7/R8 relationship so that both are hydrogen or together form a bond. These limitations move the claim closer to the active ibrutinib series, including acrylamide and related unsaturated derivatives.
Claim 5: Named compounds
Claim 5 recites specific compounds, including:
- The 3-substituted piperidine acrylamide corresponding to ibrutinib.
- The E-crotonamide analogue.
- A vinyl sulfonamide analogue.
- A propiolamide analogue.
- A 4-substituted piperidine analogue.
- A trans-4-substituted cyclohexyl acrylamide.
- R- and S-pyrrolidine acrylamides.
- R- and S-piperidine acrylamides.
- An E-dimethylaminobutenamide analogue.
A claim to a specifically named compound is generally more resistant to design-around arguments than a broad genus claim because infringement turns on whether the accused molecule has the recited structure, stereochemistry and substituents.
Claims 6 and 7: Composition and narrower compound protection
Claim 6 covers a pharmaceutical composition containing a claim 1 compound and a pharmaceutically acceptable excipient.
Claim 7 narrows claim 3 by requiring R6 and R8 to be hydrogen. It therefore captures a more limited subset of compounds within the claim 1 genus.
The supplied claim text does not include the complete language of claim 8. The analysis of claim 8 cannot extend beyond the partial text provided.
How does claim 5 cover ibrutinib?
Claim 5 directly covers ibrutinib if the claimed stereochemical configuration corresponds to the marketed R-isomer.
The relevant compound is the R-3-piperidinyl derivative containing:
- The 4-amino-3-(4-phenoxyphenyl) pyrazolopyrimidine core.
- A piperidine nitrogen substituted with a prop-2-en-1-one group.
- The R configuration at the piperidine carbon attached to the heterocyclic core.
The acrylamide is material to the pharmacology. It is an electrophilic warhead that enables irreversible BTK binding. A generic manufacturer seeking approval for ibrutinib would therefore face direct compound-patent infringement exposure while the patent remains enforceable.
A product containing a different stereoisomer, a non-acrylamide electrophile, or a modified aryl substituent would require a separate claim-construction and infringement analysis. Such changes could avoid claim 5 while remaining within claim 1, depending on the exact structure.
What is the scope of the broader genus claim?
The genus claim has meaningful breadth but is constrained by several fixed elements.
Core limitations
The claim requires the particular pyrazolo[3,4-d]pyrimidine system represented by Formula D. The formula is essential. A compound with a different fused heterocyclic core would generally fall outside the claim, even if it retained the 4-phenoxyphenyl group and acrylamide.
Aryl limitation
Ar is restricted to unsubstituted phenyl. This excludes, on the claim language, substituted phenyl groups such as:
- 4-methylphenyl;
- 4-fluorophenyl;
- 3-chlorophenyl;
- 3,4-dimethoxyphenyl; and
- heteroaryl replacements.
This limitation creates potential design-around space around the phenoxyphenyl region.
Ring limitation
Y includes several saturated ring systems:
- Cyclobutyl through cycloheptyl;
- Azetidine;
- Pyrrolidine;
- Piperidine; and
- Azepane.
The claim therefore reaches more than the piperidine structure used in ibrutinib. It also captures positional and stereochemical variants where the remaining claim elements are satisfied.
Electrophilic linker limitation
Z includes carbonyl, aminocarbonyl and sulfonyl-type groups. The claim is not limited to an acrylamide. It can cover compounds with alternative acyl and sulfonyl linkers, provided the overall Formula D relationship and R-group limitations are met.
Salt limitation
Pharmaceutically acceptable salts are expressly included. A salt-form change would not ordinarily avoid the claim if the underlying active moiety is within the claimed structure.
What patents protect ibrutinib after Patent 7,514,444?
Ibrutinib protection has involved a layered portfolio rather than a single patent. The principal categories are below.
| Protection category |
Typical subject matter |
Commercial significance |
| Core compound |
Ibrutinib and related BTK inhibitor structures |
Blocks manufacture and sale of the active molecule |
| Chemical process |
Intermediates, synthetic routes and purification |
Raises manufacturing and supply-chain barriers |
| Therapeutic use |
BTK inhibition in B-cell malignancies and immune disorders |
Supports method-of-use litigation |
| Formulation |
Solid dosage forms, excipients and release properties |
Can delay or complicate generic substitution |
| Dosing regimen |
Specific dosing schedules and treatment populations |
Supports narrower Orange Book or litigation positions |
| Combination therapy |
Ibrutinib with other anticancer agents |
Protects selected treatment protocols |
| Crystal or solid forms |
Polymorphs, solvates or defined physical forms |
May affect API and finished-dose products |
U.S. Patent 7,514,444 is the foundational chemical patent. Later continuation and divisional applications have been used to pursue additional claims directed to compounds, therapeutic methods and related commercial implementations. The enforceability of each later patent depends on its individual claims, priority chain, terminal disclaimers, prosecution history and listed expiration date.
When does U.S. Patent 7,514,444 lose exclusivity?
The commonly reported expiration date for U.S. Patent 7,514,444 is March 6, 2026. A six-month pediatric extension, if applicable to the relevant product and patent, could extend enforceable protection to September 6, 2026. The effective date must be confirmed against the patent's term-adjustment calculation and the applicable FDA pediatric-exclusivity record.
| Milestone |
Date or period |
| Earliest relevant patent-family priority |
March 6, 2006, as reflected in public patent records |
| Patent issuance |
April 7, 2009 |
| Standard reported expiration |
March 6, 2026 |
| Potential pediatric extension |
Six months |
| Possible extended endpoint |
September 6, 2026 |
| Ibrutinib FDA approval |
November 13, 2013 |
| Five-year NCE exclusivity endpoint |
November 13, 2018 |
Patent expiration and FDA exclusivity are separate. New chemical entity exclusivity expired years before the core patent. FDA approval of an ANDA can still be blocked by an unexpired Orange Book patent, a Paragraph IV dispute, a court injunction or a settlement-based launch restriction.
What is the Orange Book status of ibrutinib?
Imbruvica's Orange Book protection has included the core compound patent and later patents directed to additional aspects of ibrutinib therapy and product manufacture. Orange Book listings can change through patent-listing updates, delistings, litigation outcomes and expiration corrections.
For a generic applicant, the relevant review is claim-specific:
- Identify every patent listed for the relevant Imbruvica dosage form and indication.
- Determine whether the proposed ANDA product practices the listed claims.
- File a Paragraph IV certification where the applicant asserts that a listed patent is invalid, unenforceable or not infringed.
- Assess the 30-month stay triggered by timely patent litigation.
- Analyze any settlement restrictions and authorized-generic arrangements.
The 7,514,444 patent is most relevant to the active ingredient itself. Formulation and method patents create separate infringement questions and may have later expiration dates.
Which companies have challenged ibrutinib patents?
Publicly reported ibrutinib patent litigation has involved multiple generic-drug manufacturers, including companies such as Hetero, Natco, Cipla, Zydus, Amneal and Teva in various proceedings or market-entry contexts. The precise defendant, patent set and settlement terms vary by case.
The main legal pattern has been Paragraph IV litigation against patents covering:
- Ibrutinib as a chemical compound;
- Therapeutic use in hematologic malignancies;
- Dosage and treatment regimens;
- Pharmaceutical formulations; and
- Manufacturing or solid-form attributes.
A Paragraph IV filing is not proof that a patent is invalid or that the generic will launch. It is a statutory certification that creates a litigation pathway. Final market entry depends on settlement terms, court judgments, injunctions and the remaining Orange Book patents.
What generic entry risks exist after core-patent expiration?
Generic entry is unlikely to be determined solely by the March 2026 expiration of Patent 7,514,444.
Scenario 1: Immediate post-expiration entry
A generic applicant could launch after the core compound patent and all blocking patents expire or are otherwise cleared. This scenario produces the fastest price erosion and the highest volume transfer from Imbruvica to generic ibrutinib.
Scenario 2: Settlement-controlled entry
A Paragraph IV settlement may permit launch on a negotiated date that is earlier than the latest listed patent expiration but later than the core compound expiration. Such settlements can preserve substantial branded revenue after the foundational patent expires.
Scenario 3: Limited product entry
A generic may enter for some dosage forms or indications while remaining blocked for others. This can occur where method-of-use patents remain listed or where the generic uses a carve-out under section viii of the Hatch-Waxman framework.
Scenario 4: Litigation-driven delay
A court may uphold later patents, find infringement, or maintain a statutory stay. In that case, launch can be delayed beyond the core patent's expiration.
The commercial risk is greatest for the standard oral capsule and tablet presentations because these products have the largest substitutable market. Patent barriers directed only to a particular formulation may have less impact if a generic can lawfully use a different formulation.
How strong is the patent estate for ibrutinib?
The estate is strongest against an exact generic copy of ibrutinib during the life of the core compound patent. Claim 5 identifies the marketed R-isomer with high structural specificity, while claims 1 through 4 provide broader coverage across related analogues.
The estate is weaker against:
- A different BTK inhibitor with a non-pyrazolopyrimidine core;
- A reversible inhibitor such as pirtobrutinib;
- A molecule with a substantially modified aryl group;
- A different electrophile outside the claimed Z options; or
- A product that uses a non-infringing formulation and approved indication carve-out.
Patent strength is not equivalent to commercial durability. Ibrutinib has faced clinical competition from acalabrutinib, zanubrutinib and pirtobrutinib, each of which can reduce the market value of residual patent life.
How does ibrutinib compare with competing BTK inhibitors?
| Drug |
Company |
BTK binding |
Main competitive issue |
| Ibrutinib |
AbbVie/Janssen |
Irreversible covalent |
First-mover scale, but broader off-target activity |
| Acalabrutinib |
AstraZeneca |
Irreversible covalent |
Selectivity and tolerability competition |
| Zanubrutinib |
BeiGene |
Irreversible covalent |
Strong efficacy and increasing share in B-cell malignancies |
| Pirtobrutinib |
Lilly |
Reversible noncovalent |
Activity after covalent BTK inhibitor resistance |
These products do not automatically infringe Patent 7,514,444 because their structures differ materially. Their own patent estates are separate. Competitive substitution can therefore reduce revenue exposure even before generic ibrutinib entry.
What manufacturing and IP barriers remain?
Ibrutinib manufacturing barriers include:
- Control of stereochemistry at the piperidine center;
- Preparation of the substituted pyrazolopyrimidine intermediate;
- Installation of the acrylamide without unwanted polymerization or degradation;
- Control of residual solvents and genotoxic impurities;
- API crystallization and particle-size control;
- Finished-dose stability; and
- Regulatory demonstration of pharmaceutical equivalence.
A generic manufacturer can avoid a process patent by using a different synthetic route, but it cannot avoid the compound patent if the final product is the claimed molecule during the patent term. Process patents therefore become more important after core compound expiration.
What licensing deals affect ibrutinib commercialization?
Pharmacyclics developed ibrutinib and entered into a global collaboration with Janssen Biotech, an affiliate of Johnson & Johnson. AbbVie acquired Pharmacyclics in 2015 and became the principal owner of Pharmacyclics' commercial rights. Janssen has remained a commercialization partner in the collaboration.
The collaboration affects:
- Ownership and prosecution of the patent estate;
- Global commercialization;
- Revenue allocation;
- Regulatory strategy; and
- Litigation and generic-settlement decisions.
Key Takeaways
- U.S. Patent 7,514,444 is a foundational ibrutinib compound patent.
- Claim 5 directly recites the marketed R-ibrutinib structure.
- Claim 1 reaches a broader genus of pyrazolopyrimidine BTK inhibitors with specified ring and electrophilic linker options.
- Claims 6 and 7 extend protection to pharmaceutical compositions and narrower chemical subsets.
- The commonly reported expiration date is March 6, 2026, with a possible six-month pediatric extension.
- Later formulation, method-of-use, dosing, process and solid-form patents may create barriers after core compound expiration.
- Paragraph IV litigation and settlement agreements are central to the timing of generic ibrutinib entry.
- A generic copy faces the greatest risk under the exact compound claim; structurally distinct BTK inhibitors generally require separate analysis.
- Acalabrutinib, zanubrutinib and pirtobrutinib create competitive erosion independent of patent expiry.
- Pharmacyclics, AbbVie and Janssen control the principal commercial and patent interests associated with Imbruvica.
Frequently Asked Questions
Does Patent 7,514,444 cover both R-ibrutinib and S-ibrutinib?
Claim 5 recites both R- and S-configured piperidine analogues in the supplied text. The marketed product is the R-isomer. Whether a particular stereoisomer is covered depends on the exact claim language and structural depiction.
Can a generic launch immediately when Patent 7,514,444 expires?
Not necessarily. Later Orange Book patents, litigation settlements, court orders and indication-specific method claims may delay or limit launch.
Is ibrutinib's acrylamide required for BTK inhibition?
The acrylamide is a key covalent-binding group in ibrutinib. Patent claim coverage, however, depends on the claimed structural formula, not solely on pharmacological activity.
Does changing ibrutinib to a salt avoid the patent?
No. Claim 1 expressly includes pharmaceutically acceptable salts. A salt-form change ordinarily does not avoid a compound claim covering the active moiety.
Are acalabrutinib and zanubrutinib covered by Patent 7,514,444?
They are generally treated as separate BTK inhibitor molecules with different structures and patent estates. Coverage must be determined by comparing each molecule with the complete Formula D limitations and the asserted claims.
References
-
U.S. Patent No. 7,514,444. (2009). Inhibitors of Bruton's tyrosine kinase. U.S. Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2013). FDA approves Imbruvica for patients with mantle cell lymphoma. https://www.fda.gov
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Imbruvica prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov
-
AbbVie Inc. (2024). Annual report. https://investors.abbvie.com
-
Pharmacyclics, LLC, & Janssen Biotech, Inc. (2011). Ibrutinib collaboration and commercialization materials. Company and regulatory filings.
